GE
ALXN

General Electric’s Alexion Pharmaceuticals ALXN Stock Holding History

General Electric’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-988,901
Closed -$115M – 189
2016
Q2 		$115M Buy
988,901
+116,900
+13% +$16.6M 0.6% 59
2016
Q1 		$121M Sell
872,001
-48,098
-5% -$7.06M 0.62% 55
2015
Q4 		$176M Sell
920,099
-9,805
-1% -$1.71M 0.85% 41
2015
Q3 		$145M Sell
929,904
-12,080
-1% -$2.2M 0.35% 49
2015
Q2 		$170M Buy
941,984
+141,500
+18% +$24.4M 0.38% 43
2015
Q1 		$139M Buy
800,484
+117,406
+17% +$21.3M 0.32% 55
2014
Q4 		$126M Buy
683,078
+2,482
+0.4% +$460K 0.3% 63
2014
Q3 		$113M Buy
680,596
+61,018
+10% +$10M 0.29% 66
2014
Q2 		$96.8M Buy
619,578
+133,373
+27% +$21.1M 0.44% 72
2014
Q1 		$74M Sell
486,205
-4,114
-0.8% -$654K 0.35% 77
2013
Q4 		$65.2M Buy
490,319
+14,222
+3% +$1.71M 0.31% 80
2013
Q3 		$55.3M Buy
476,097
+405,483
+574% +$44.5M 0.28% 81
2013
Q2 		$6.51M Buy
+70,614
New +$6.8M 0.03% 147

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

General Electric's ALXN Position: Q3 2016 in Review

General Electric sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 988,901 shares — an estimated $115M sold.

General Electric first reported a position in ALXN in Q2 2013 and held it in 13 quarters. The position peaked at $176M in Q4 2015. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • General Electric reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • General Electric sold 988,901 Alexion Pharmaceuticals shares in Q3 2016, an estimated $115M.
  • General Electric first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • General Electric's Alexion Pharmaceuticals position peaked at $176M in Q4 2015.
  • 517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on General Electric's 13F filing for Q3 2016, filed 10 Nov 2016.